全文获取类型
收费全文 | 3071篇 |
免费 | 150篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 75篇 |
妇产科学 | 60篇 |
基础医学 | 471篇 |
口腔科学 | 134篇 |
临床医学 | 236篇 |
内科学 | 611篇 |
皮肤病学 | 38篇 |
神经病学 | 332篇 |
特种医学 | 70篇 |
外科学 | 298篇 |
综合类 | 8篇 |
一般理论 | 1篇 |
预防医学 | 238篇 |
眼科学 | 117篇 |
药学 | 240篇 |
中国医学 | 22篇 |
肿瘤学 | 252篇 |
出版年
2023年 | 17篇 |
2022年 | 13篇 |
2021年 | 50篇 |
2020年 | 53篇 |
2019年 | 71篇 |
2018年 | 81篇 |
2017年 | 70篇 |
2016年 | 81篇 |
2015年 | 79篇 |
2014年 | 119篇 |
2013年 | 165篇 |
2012年 | 258篇 |
2011年 | 291篇 |
2010年 | 149篇 |
2009年 | 119篇 |
2008年 | 197篇 |
2007年 | 213篇 |
2006年 | 220篇 |
2005年 | 215篇 |
2004年 | 206篇 |
2003年 | 178篇 |
2002年 | 153篇 |
2001年 | 11篇 |
2000年 | 11篇 |
1999年 | 18篇 |
1998年 | 15篇 |
1997年 | 16篇 |
1996年 | 12篇 |
1995年 | 13篇 |
1994年 | 16篇 |
1993年 | 12篇 |
1992年 | 13篇 |
1991年 | 9篇 |
1990年 | 14篇 |
1989年 | 6篇 |
1988年 | 3篇 |
1987年 | 8篇 |
1986年 | 8篇 |
1985年 | 4篇 |
1984年 | 8篇 |
1983年 | 8篇 |
1982年 | 3篇 |
1981年 | 6篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1977年 | 2篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1966年 | 2篇 |
排序方式: 共有3227条查询结果,搜索用时 15 毫秒
1.
Javad Sharifi‐Rad Shahira M. Ezzat Mahitab H. El Bishbishy Dima Mnayer Farukh Sharopov Ceyda S. Kl Monica Neagu Carolina Constantin Mehdi Sharifi‐Rad Maria Atanassova Silvana Nicola Giuseppe Pignata Bahare Salehi Patrick V. T. Fokou Natlia Martins 《Phytotherapy research : PTR》2020,34(7):1474-1518
Rosmarinus species are aromatic plants that mainly grow in the Mediterranean region. They are widely used in folk medicine, food, and flavor industries and represent a valuable source of biologically active compounds (e.g., terpenoids, flavonoids, and phenolic acids). The extraction of rosemary essential oil is being done using three main methods: carbon dioxide supercritical extraction, steam distillation, and hydrodistillation. Furthermore, interesting antioxidant, antibacterial, antifungal, antileishmanial, anthelmintic, anticancer, anti‐inflammatory, antidepressant, and antiamnesic effects have also been broadly recognized for rosemary plant extracts. Thus the present review summarized data on economically important Rosmarinus officinalis species, including isolation, extraction techniques, chemical composition, pharmaceutical, and food applications. 相似文献
2.
3.
Marino Clavio MD Elena Crisà MD Maurizio Miglino MD Fabio Guolo MD Manuela Ceccarelli MD Flavia Salvi MD Bernardino Allione MD Dario Ferrero MD Enrico Balleari MD Carlo Finelli MD Antonella Poloni MD Carmine Selleri MD Paolo Danise MD Daniela Cilloni MD Anna Angela Di Tucci MD Gianni Cametti MD Roberto Freilone MD Renato Fanin MD Catia Bigazzi MD Renato Zambello MD Monica Crugnola MD Esther N. Oliva MD Riccardo Centurioni MD Francesco Alesiani MD Massimo Catarini Andrea Castelli Antonio Abbadessa Silvana F. Capalbo Pellegrino Musto MD Emanuele Angelucci MD Valeria Santini MD 《Cancer》2021,127(12):2015-2024
4.
5.
6.
7.
Bahare Salehi Dmitry A. Konovalov Pascaline Fru Petrina Kapewangolo Gregorio Peron Mileski S. Ksenija Susana M. Cardoso Olivia R. Pereira Manisha Nigam Silvana Nicola Giuseppe Pignata Simona Rapposelli Simona Sestito Nanjangud V. Anil Kumar María de la Luz Cdiz‐Gurrea Antonio Segura‐Carretero Abhay P. Mishra Mehdi Sharifi‐Rad William C. Cho Yasaman Taheri William N. Setzer Javad Sharifi‐Rad 《Phytotherapy research : PTR》2020,34(9):2140-2158
The family Arecaceae includes 181 genera and 2,600 species with a high diversity in physical characteristics. Areca plants, commonly palms, which are able to grow in nearly every type of habitat, prefer tropical and subtropical climates. The most studied species Areca catechu L. contains phytochemicals as phenolics and alkaloids with biological properties. The phenolics are mainly distributed in roots followed by fresh unripe fruits, leaves, spikes, and veins, while the contents of alkaloids are in the order of roots, fresh unripe fruits, spikes, leaves, and veins. This species has been reputed to provide health effects on the cardiovascular, respiratory, nervous, metabolic, gastrointestinal, and reproductive systems. However, in many developing countries, quid from this species has been associated with side effects, which include the destruction of the teeth, impairment of oral hygiene, bronchial asthma, or oral cancer. Despite these side effects, which are also mentioned in this work, the present review collects the main results of biological properties of the phytochemicals in A. catechu. This study emphasizes the in vitro and in vivo antioxidant, antimicrobial, anticancer, and clinical effectiveness in humans. In this sense, A. catechu have demonstrated effectiveness in several reports through in vitro and in vivo experiments on disorders such as antimicrobial, antioxidant, or anticancer. Moreover, our findings demonstrate that this species presents clinical effectiveness on neurological disorders. Hence, A. catechu extracts could be used as a bioactive ingredient for functional food, nutraceuticals, or cosmeceuticals. However, further studies, especially extensive and comprehensive clinical trials, are recommended for the use of Areca in the treatment of diseases. 相似文献
8.
9.
Paulo Cceres Guido Natalia Riva Roberto Caraballo Gabriela Reyes Marina Huaman Robinson Gutierrez Silvana Agostini Sandra Fabiana Delaven Carlos A. Prez Montilla Facundo García Bournissen Paula Schaiquevich 《Epilepsia》2021,62(1):e7-e12
Growing interest in the clinical use of cannabidiol (CBD) as adjuvant therapy for pediatric refractory epileptic encephalopathy emphasizes the need for drug treatment optimization. The aim of this study was to characterize the pharmacokinetics of CBD in pediatric patients with refractory epileptic encephalopathy receiving an oil‐based oral solution. To evaluate CBD concentrations, six serial blood samples per patient were collected after the morning dose of CBD, at least 21 days after the beginning of treatment. Twelve patients who received a median (range) dose of 12.2 (5.3‐19.4) mg/kg/d (twice daily) were included in the analysis. Median (range) CBD time to maximum plasma concentration, maximum plasma concentration, and area under the concentration versus time curve up to 6 hours after dosing were 3.2 hours (1.9‐6.2), 49.6 ng/mL (14.4‐302.0), and 226.3 ng ? h/mL (70.5‐861.3), respectively. CBD systemic exposure parameters were in the lower range of previous reports in pediatric patients receiving doses in a similar range. Most of our patients (83%) showed little CBD plasma level fluctuation during a dosing interval, comparable to that encountered after oral administration of an extended release drug delivery system. CDB administration was generally safe and well tolerated, and a novel levothyroxine‐CBD interaction was recorded. Similar to other studies, large interindividual variability in CBD exposure was observed, encouraging the use of CBD therapeutic drug monitoring. 相似文献
10.
Erika Borlenghi Chiara Cattaneo Elisa Cerqui Silvana Archetti Diego Bertoli Daniela Bellotti Doriana Gramegna Giulia Soverini Margherita Oberti Francesca Schieppati Chiara Pagani Angela Passi Margherita Sciumé Mirko Farina Cecilia Carbone Claudia Crippa Daniela Dalceggio Alessandra Tucci Giuseppe Rossi 《Hematological oncology》2020,38(5):754-762
Consolidation treatment in acute myeloid leukemia (AML) patients achieving complete remission (CR) is warranted. High-dose cytarabine (HDAC) is considered first choice in favorable risk and an option in intermediate-risk AML. However, its optimal dose and schedule, as well as the benefit of additional chemotherapy agents remain controversial. Herein, we report on the long-term outcome of consecutive unselected AML patients treated with repeated courses of HDAC, with the addition of idarubicin, followed by autologous peripheral blood stem cell (PBSC) support, in order to limit toxicity, according to Northern Italy Leukemia Group (NILG) AML-01/00 study (EUDRACT number 00400673). Among 338 patients consecutively diagnosed from 2001 to 2017 at our center, 148 with high-risk AML (adverse cytogenetic, isolated FLT3-internal tandem duplication mutation, refractory to first induction) were addressed to allogeneic stem cell transplant. All other cases, 186 patients (55%), median age 53 (range 19–75), were considered standard-risk and received the NILG AML-01/00 program. After achieving CR, patients were mobilized with cytarabine 8 g/sqm to collect autologous CD34+-PBSC and received three consolidation cycles with HDAC (20 g/sqm) plus idarubicin (20 mg/sqm) per cycle, followed by reinfusion of limited doses of CD34+ PBSC (1-2x106/kg). The program was completed by 160 (86%) patients. Toxicity was acceptable. Neutrophils recovered a median of 10 days. Treatment-related mortality was 3/160 (1.8%). After a median follow-up of 66.4 months, overall survival (OS) and relapse-free survival (RFS) at 5-years were 61.4% and 52.4%, respectively. Twenty-eight selected patients aged >65 had similar outcomes. According to European leukemia net-2010 classification, the OS and RFS at 5-years were 76.4% and 65% in favorable risk, without differences between molecular subgroups, 52.3% and 47.2% in Intermediate-I, 45.2% and 36.5% in Intermediate-II risk patients, respectively. In conclusion, consolidation including repeated courses of high dose cytarabine and idarubicin, with limited PBSC support, proved feasible and very effective in nonhigh risk patients. The incorporation of novel agents in its backbone may be tested to further improve patient's prognosis. 相似文献